(NYSE: CTLT) Catalent's forecast annual revenue growth rate of 3.62% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.54%.
Catalent's revenue in 2023 is $4,495,000,000.On average, 6 Wall Street analysts forecast CTLT's revenue for 2024 to be $789,807,633,300, with the lowest CTLT revenue forecast at $784,567,854,876, and the highest CTLT revenue forecast at $794,059,162,039. On average, 7 Wall Street analysts forecast CTLT's revenue for 2025 to be $841,029,865,516, with the lowest CTLT revenue forecast at $828,015,147,174, and the highest CTLT revenue forecast at $849,727,075,660.
In 2026, CTLT is forecast to generate $903,688,356,709 in revenue, with the lowest revenue forecast at $886,991,047,242 and the highest revenue forecast at $921,790,704,125.